MTOR and cancer: Hyperglycemia occurs in 20–60% of cancer patients as a result of the use of corticosteroids during chemotherapy treatment or due to specific anticancer agents, such as mammalian target of rapamycin (mTOR) inhibitors, phosphoinositide-3 kinase (PI3K) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, immune checkpoint inhibitors, among others [1–9].